Recombinant Human Gamma-Interferon in Primary Hepatocellular Carcinoma
Open Access
- 1 October 1985
- journal article
- research article
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 78 (10) , 826-829
- https://doi.org/10.1177/014107688507801007
Abstract
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.This publication has 9 references indexed in Scilit:
- Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.Journal of Biological Chemistry, 1984
- Interferon: antitumor actions.1984
- Current status of interferon therapyThe Medical Journal of Australia, 1984
- Interferon and cancer.BMJ, 1983
- Toxic Effects of InterferonScience, 1983
- Depressed natural killer cell activity in patients with hepatocellular carcinoma in vitro effects of interferon and levamisoleCancer, 1982
- The kidney and liver diseases.Journal of Clinical Pathology, 1981
- Reporting results of cancer treatmentCancer, 1981
- Inhibition of Murine Osteogenic Sarcomas by Treatment With Type I or Type II Interferon2JNCI Journal of the National Cancer Institute, 1978